Amgen Inc. (VIE:AMGN)

Market Cap	152.71B
Revenue (ttm)	30.66B
Net Income (ttm)	5.97B
Shares Out	n/a
EPS (ttm)	11.02
PE Ratio	25.58
Forward PE	16.01
Dividend	8.52 (3.01%)
Ex-Dividend Date	Nov 21, 2025

Volume	129
Average Volume	53
Open	281.05
Previous Close	282.20
Day's Range	278.95 - 282.80
52-Week Range	230.50 - 307.30
Beta	n/a
RSI	54.25
Earnings Date	Feb 3, 2026

About Amgen

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1980
• Employees: 28,000
• Stock Exchange: Vienna Stock Exchange
• Ticker Symbol: AMGN

Financial Performance

In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.

Financial numbers in USD